title: Endocrine Long-Term Follow-Up of Children with Neurofibromatosis Type 1 and Optic Pathway Glioma .
abstract: OBJECTIVE
  Children with optic pathway glioma (OPG) face sequelae related to tumour location and treatment modalities. We aimed to assess the prevalence of hypothalamic-pituitary dysfunctions in children with neurofibromatosis type 1 (NF1) and OPG who did not receive radiotherapy or surgical resection. The causative role of tumour location on endocrinopathy development is investigated.
  
  
  METHODS
  A retrospective follow-up study of 40 children with NF1 and OPG evaluated between August 1996 and May 2015 was undertaken. Patients who underwent radiotherapy or surgical resection were excluded and 36 patients were studied. Tumour location was classified according to the Dodge criteria: stage I, optic nerve alone; stage II, optic chiasm with or without optic nerve involvement; and stage III, involvement of the hypothalamus or other adjacent structures.
  
  
  RESULTS
  Endocrinopathies were diagnosed in 20/36 (55.6%) children during a mean follow-up of 9.1 (0.2-13.6) years: 0/4 OPGs were Dodge stage I, 12/21 (57.1%) stage II, and 8/11 (72.7%) stage III. The first endocrinopathy was found at a mean age of 7.4 (5.0-13.2) years, 2.4 (0-6.7) years after tumour diagnosis. We found growth hormone deficiency (GHD; 36.1%), central precocious puberty (33.3%), obesity with insulin resistance/impaired glucose tolerance (11.1%), early puberty (5.5%), GH excess (5.5%), ACTH deficiency (5.5%), hypogonadotropic hypogonadism (2.7%), and thyrotropin deficiency (2.7%). GHD was transient in all of those who were retested.
  
  
  CONCLUSIONS
  This population is at high risk of endocrinopathies due to tumour location. Lifelong endocrine follow-up is recommended. .
authors.forename: Ilaria
authors.initials: I
authors.lastname: Sani
authors.forename: Assunta
authors.initials: A
authors.lastname: Albanese
mesh_terms: D002648:Child; D002675:Child, Preschool; D004700:Endocrine System Diseases / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D008297:Male; D009456:Neurofibromatosis 1 / Q000188:drug therapy / Q000453:epidemiology; D019574:Optic Nerve Neoplasms / Q000188:drug therapy / Q000453:epidemiology; D012189:Retrospective Studies